Dexcom
Matthew Johnson is a seasoned professional with extensive experience in clinical science and research, currently serving as the Senior Director of Clinical Science at Dexcom since October 2015. Responsibilities include overseeing global clinical science activities and directing clinical science initiatives for product development, particularly in type 2 diabetes. Prior roles at Dexcom involved building teams for clinical research and supporting new product launches. Previously, Matthew held academic positions at Mayo Clinic, contributing to research on artificial pancreas systems and clinical trial management. Other consulting roles spanned regulatory guidance and clinical trials. Matthew holds a BS and Ph.D. in Nutrition and Toxicology and Integrative Biology from the University of California, Berkeley.
This person is not in any teams
This person is not in any offices
Dexcom
43 followers
Founded in 1999, Dexcom, Inc. (NASDAQ: DXCM), is developing and marketing Continuous Glucose Monitoring (CGM) systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes. The company is the leader in transforming diabetes care and management by providing CGM technology to help patients and healthcare professionals better manage diabetes.